425 Participants Needed

ApricityCare Program for Cancer

BA
Overseen ByBilal A Siddiqui, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines how effectively ApricityCare helps people with cancer manage treatment side effects. The goal is to determine if early detection of side effects can prevent them from worsening, allowing patients to continue their treatment longer. Participants can report symptoms anytime via an app or phone call, and nurses will quickly address these issues. Individuals with confirmed cancer, particularly prostate, kidney, or bladder cancer, who plan to start anti-cancer therapy, may be suitable for this trial. Participants must have a smartphone and be comfortable using it for trial activities. As an unphased trial, this study offers a unique opportunity to contribute to innovative cancer care solutions.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

What prior data suggests that the ApricityCare Program is safe for cancer patients?

Research shows that the ApricityCare Program helps cancer patients manage treatment side effects. Studies have found that the program can detect early signs of side effects, preventing them from worsening. This may result in fewer patients needing to stop treatment due to these side effects.

In other studies of similar programs, up to 16% of patients experienced immune-related side effects when using certain cancer treatments. However, the ApricityCare Program manages these side effects early. It offers 24/7 support, which can help prevent the side effects from becoming severe.

While side effects can occur, the program aims to catch and treat them early, potentially reducing the likelihood of patients having to stop their cancer treatment.12345

Why are researchers excited about this trial?

Researchers are excited about the ApricityCare Program for cancer patients because it offers a unique 24/7 support system through a mobile app and phone access, allowing patients to instantly report symptoms and receive guidance. Unlike traditional care that might involve scheduled check-ups, this program ensures real-time monitoring and immediate response, potentially preventing complications before they escalate. Additionally, all interactions with ApricityCare nurses are seamlessly integrated into the patient's electronic health records, enhancing continuity of care and personalized treatment plans. This innovative approach aims to improve patient outcomes by providing timely intervention and tailored support.

What evidence suggests that the ApricityCare Program is effective for reducing therapy discontinuation due to toxicity in cancer patients?

Research shows that the ApricityCare program helps detect and manage side effects early for cancer patients. In this trial, participants will have 24/7 access to the ApricityCare service, enabling them to report symptoms at any time. Studies have found that using ApricityCare reduces the risk of stopping cancer treatment due to severe side effects. Nurses review these reports and quickly provide advice or involve doctors if necessary. Early evidence suggests that this approach prevents side effects from worsening, helping patients continue their treatment smoothly.12467

Are You a Good Fit for This Trial?

Inclusion Criteria

I have been diagnosed with metastatic cancer, specifically prostate, kidney, or bladder cancer for the initial phase.
I am scheduled for treatment that targets cancer throughout my body.
I can understand and am willing to sign the consent form.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants use the ApricityCare program to report symptoms and manage treatment-related adverse events

1 year
Weekly check-ins via app or phone

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • ApricityCare Program

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Metastatic CancerExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

Citations

A pilot study of the ApricityCare program for early detection ...

This phase IV clinical trial evaluates ApricityCare's impact on treatment outcomes for patients receiving systemic therapies for metastatic cancer.

A Study of the ApricityCare Program for Early Detection ...

To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare. Investigators want to learn if ...

A phase IV study of ApricityCARE program for cancer ...

A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority ...

A pilot study of the ApricityCare program for early detection ...

Methods: This phase IV clinical trial evaluates ApricityCare's impact on treatment outcomes for patients receiving systemic therapies for metastatic cancer.

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial ...

The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C. ...

A Study of the ApricityCare Program for Early Detection ...

To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare.

A pilot study of the ApricityCare program for early detection ...

A pilot study of the ApricityCare program for early detection and management of treatment-related adverse events in patients with metastatic cancer. A pilot ...